Insights

Why Novavax Is Crushing It This Week

What happened
Novavax (NASDAQ: NVAX) is absolutely crushing it this week. Shares of the vaccine maker were up 29.9% for the week as of the market close on Thursday, according to data from S&P Global Market Intelligence. 
Investors appear to be jumping back on the Novavax bandwagon after a couple of recent positive developments. The U.S. Food and Drug Administration (FDA) announced last week that it plans to convene an advisory committee to review the Emergency Use Authorization (EUA) filing for COVID-19 vaccine NVX-CoV2373. Also, on Wednesday Novavax requested expanded EUA in Great Britain for its vaccine in adolescents ages 12 to 17. 
So what
To be sure, one week of strong gains doesn’t make up for the extended slump the vaccine stock has experienced. Novavax’s shares are still nearly 80% below the high set in September 2021.
But the FDA’s decision to convene the Vaccines and Related Biological Products Advisory Committee (VRBPAC) to review Novavax’s EUA filing is great news for the company. After multiple delays, Novavax appears to be finally on the right track to win U.S. authorization for its COVID-19 vaccine.
The request for expanded EUA in Great Britain in immunizing adolescents isn’t nearly as significant of a catalyst for Novavax. However, it’s nonetheless an important step for the company in its goal to increase sales.
Image source: Getty Images.

Now what
VRBPAC is scheduled to meet on June 7 to review the EUA submission for NVX-CoV2373. But there’s another key milestone for Novavax that will come even sooner. The company will provide its first-quarter update on Monday, May 9, after the market close. 
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

Novavax (NASDAQ: NVAX) is absolutely crushing it this week. Shares of the vaccine maker were up 29.9% for the week as of the market close on Thursday, according to data from S&P Global Market Intelligence

Investors appear to be jumping back on the Novavax bandwagon after a couple of recent positive developments. The U.S. Food and Drug Administration (FDA) announced last week that it plans to convene an advisory committee to review the Emergency Use Authorization (EUA) filing for COVID-19 vaccine NVX-CoV2373. Also, on Wednesday Novavax requested expanded EUA in Great Britain for its vaccine in adolescents ages 12 to 17. 

So what

To be sure, one week of strong gains doesn’t make up for the extended slump the vaccine stock has experienced. Novavax’s shares are still nearly 80% below the high set in September 2021.

But the FDA’s decision to convene the Vaccines and Related Biological Products Advisory Committee (VRBPAC) to review Novavax’s EUA filing is great news for the company. After multiple delays, Novavax appears to be finally on the right track to win U.S. authorization for its COVID-19 vaccine.

The request for expanded EUA in Great Britain in immunizing adolescents isn’t nearly as significant of a catalyst for Novavax. However, it’s nonetheless an important step for the company in its goal to increase sales.

Image source: Getty Images.

Now what

VRBPAC is scheduled to meet on June 7 to review the EUA submission for NVX-CoV2373. But there’s another key milestone for Novavax that will come even sooner. The company will provide its first-quarter update on Monday, May 9, after the market close. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!